Amgen Inc. (NASDAQ:AMGN) has sold its office campus in Deerfield, Illinois, for $151 million. The buyer is an entity tied to Mesirow, a financial services firm based in Chicago.
Amgen is not leaving. It has signed a long-term lease to stay on the roughly 660,000-square-foot campus, where it occupies one of the three buildings. The shares rose 2.11% to close at $414.61.
READ ALSO: A Failed Cholesterol Drug Raises the Stakes for Amgen (AMGN) and Eli Lilly (LLY) Too
A Sale and Leaseback Turns a Building Into Cash Without New Debt:
The mechanics are simple. A company that owns a building sells it to an investor, then rents the same building back and carries on working there.
Nothing changes operationally. What changes is the balance sheet. An illiquid asset becomes cash, and the company avoids issuing shares or borrowing to raise the same money.
Rates are both the reason to do this and the reason it costs something. Amgen raises money without issuing shares, but the buyer prices the rent off the same interest rates everyone else is paying, and the lease still sits on the balance sheet as an obligation.
Amgen has a particular reason to care. The company carries roughly $57 billion of debt, much of it taken on to buy Horizon Therapeutics, and reducing that load has been a stated priority.
There is a logic to which assets get sold first. Nobody buys a pharmaceutical company for its offices. Laboratories, manufacturing plants and patents are what produce the returns, and a corporate campus produces none of them while still sitting on the balance sheet. Selling the building and keeping the desks changes nothing about what the company does.
DON’T MISS: Amgen (AMGN) Fell 5% on a Drug That Isn’t Even Its Own. Here’s the Lp(a) Bet Now in Question
The Rent Does Not Go Away:
A sale and leaseback is not free money. The company swaps an asset it owned outright for a stream of rent payments it now owes for years.
If the building was genuinely surplus to requirements, selling it is straightforward good sense. If it is a building the company needs, then Amgen has converted ownership into a long-term liability in exchange for a single payment.
Scale is the other thing to keep in proportion. Set against roughly $57 billion of debt, $151 million is not deleveraging. What it shows is which assets management is willing to part with.
That makes the interesting question whether this is one transaction or the beginning of a program. A single campus sale is housekeeping. A series of them would tell you something about how urgently management wants cash, at a moment when the shares have already risen roughly half over twelve months.
Conclusion:
Amgen has converted a Deerfield office campus into $151 million of cash while continuing to occupy it, which raises money without issuing shares or borrowing at today’s rates. For a company carrying around $57 billion of debt from the Horizon deal, that is a sensible use of an asset it does not need to own. However, the sum is immaterial against Amgen’s size, the rent is now a long-term obligation, and one transaction tells you very little on its own. The number to watch is total debt at the next quarterly report, because that is where you find out whether this was housekeeping or the start of something larger.
Market Sentiment:
Amgen Inc. was held by 66 hedge funds with a combined stake value of about $3.1 billion at the end of Q2 2026 in the Insider Monkey database. This is up from 65 hedge fund holders with a cumulative investment value of around $1.6 billion in the previous quarter.
READ NEXT: Visa (V) vs American Express (AXP): Which is a Better Stock to Buy and Twilio (TWLO) Keeps Climbing as Investors Rediscover its AI Business
This article is originally published at Insider Monkey.
